Last updated on May 2020

A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors

Brief description of study

To better understand the safety and tolerability of ALKS 4230 in humans

Detailed Study Description

To investigate the safety and tolerability of ALKS 4230, determine the recommended Phase 2 dose (RP2D) and assess anti-tumor activity in Monotherapy and ALKS 4230 in Combination with pembrolizumab.

Clinical Study Identifier: NCT02799095

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.